Our meta-analysis found that high expression galectin-1 and a low level of galectin-4 or galectin-9 were associated with worse prognosis, while galectin-3 expression did not show a correlation with prognosis and other clinical characteristics in pancreatic cancer patients. The gene discussed is LGALS3; the disease is pancreatic neoplasm.